Patent issued for identifying patients with substance use genetic markers

The US Patent and Trademark Office issued patent number 12,221,654 on 11 February, for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04. The AD04 treatment first detects the TT genotype of rs1042173 in the serotonin transporter gene (SLC6A4).